Facebook
Twitter
LinkedIn
ForwardThe Age of Disease Modification in Alzheimer’s Disease: A Grand Rounds Series on the Practical Implementation of Amyloid Targeting Therapies into Clinical Practice
Program Description
For the first time in the history of AD management, a class of therapy designed to alter the disease course for patients is finally a reality in the form of anti-amyloid beta monoclonal antibodies (anti-Aβ mAbs). And while this development represents a monumental shift in the treatment of this progressive disease, it unlocks a whole host of new challenges for clinicians in the form of significant adjustment of practice norms. On top of requiring a baseline understanding of a new class of medication, this advance also requires a variety of logistical changes that institutions must learn to navigate. Accordingly, this program explores general principles of anti-Aβ mAb implementation alongside practical questions provided directly by an institution in the early phases of setting up their own processes for initiation and use of these agents.
Target Audience
This program is intended for neurologists, geriatricians, geriatrics psychiatrists, advanced practice providers (APPs), and other health professionals involved in the care of patients with mild cognitive impairment and early AD.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Review current recommendations/best practices to identify and counsel individuals eligible for new and emerging DMTs anti-Aβ mAbs
- Evaluate the safety, efficacy, and administration/monitoring requirements of approved and emerging anti-Aβ mAbs to optimize treatment selection and long-term use for eligible patients
- Appraise the identification and management strategies for ARIA to prepare for timely recognition of and effective response to these events
James R. Bateman, MD, MPH
Assistant Professor of Neurology, Psychiatry and Behavioral Medicine, and Geriatrics
Wake Forest University School of Medicine
Winston-Salem, NC
This activity is jointly provided by Medical Education Resources (MER) and Efficient LLC.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Efficient LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statement
Staff Disclosures
Efficient LLC and Medical Education Resources' planners and managers have no financial relationships to disclose.
Faculty Disclosures
Dr. Bateman reported the following relationships:
- Grants/Research Support: Alzheimer’s Association; Dementia Alliance of North Carolina
- Consulting Fees: Medscape, NovoNordisk
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Efficient LLC, and/or Eisai and Lilly. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Commercial Support
This activity is supported by educational grant from Lilly.
Media
Internet
Available Credit
- 1.00 AMA PRA Category 1 Credit™